Lao Saal

CEO at SAGA Diagnostics

Dr. Saal graduated from Columbia University, New York, with MD and PhD degrees, and has performed cancer research at the National Human Genome Research Institute, NIH, and the Memorial Sloan-Kettering Cancer Center.  He is Associate Professor, Division of Oncology, Lund University, and Heads the Translational Oncogenomics Unit.

In 2016 he co-founded SAGA Diagnostics AB, a cancer genomics company providing products and services to pharma, academia, and healthcare that enable ultrasensitive quantification of tumor DNA in cancer liquid biopsies and tissues (http://sagadiagnostics.com).

SAGA_Lao_Saal_BioTech_Pharma_Summit_2021_Profile

Title: Applications of ultrasensitive circulating tumor DNA measurements to 0.001% VAF in cancer liquid biopsies using SAGAsafe (IBSAFE) digital chemistry